Pharma Mar (PHMMF) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Pharma Mar (NASDAQ:PHMMF) from a sell rating to a hold rating in a research note published on Tuesday.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Shares of Pharma Mar (NASDAQ:PHMMF) opened at 3.2678 on Tuesday. Pharma Mar has a 12-month low of $2.13 and a 12-month high of $3.65. The company’s market capitalization is $722.16 million. The company has a 50-day moving average price of $3.06 and a 200 day moving average price of $2.95.

WARNING: “Pharma Mar (PHMMF) Rating Increased to Hold at Zacks Investment Research” was posted by Mideast Time and is owned by of Mideast Time. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at

5 Day Chart for NASDAQ:PHMMF

Get a free copy of the Zacks research report on Pharma Mar (PHMMF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.